Abbott Laboratories Corporation

John D Benson

Marc L Masor

Debra L Ponder

Michael B Montalto

Gary E Katz

John B Lasekan

Matthew A Kuchan

Jeffrey Harris Baxter

David V Diodato

James L Leach

Robin J Halter

David A Borror

Margaret H Dohnalek

Susan E Carlson

Bruce Edward Molitor

Karin M Ostrom

Marlene W Borschel

Helen R Churella

Michael J Neylan

Merlin D Breen

William C MacLean, Jr

Merle D Breen

Alan D Strickland

William R Treem

The present invention is directed to a method for increasing the bone mineralization of a human, and more preferably an infant or toddler. The method comprises administering to said human a source of calcium and a fat blend that is low in palmitic acid. The enhanced mineralization results in the production of a higher peak bone mass and correspondingly lowers the incidence of osteoporosis.

Method for improving bone mineralization

The invention is directed to an improved infant formula containing a lipid blend that softens the firmer stools associated with typical infant formula. A specific formula in accordance with the invention comprises carbohydrates, proteins, vitamins and minerals and a lipid mixture of high oleic safflower oil, soy oil and coconut oil at specific levels and ratios. The invention also discloses novel mixtures of fatty acids that provides infant stool patterns more closely resembling the breast-fed infant.

Infant formula and methods of improving infant stool patterns

Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), e.g., arachidonic acid (AA), and docosahexaenoic acid (DHA), essentially free of cholesterol, are described for use in methods for reducing the incidence of necrotizing enterocolitis. Compositions from egg yolk lipids are preferred as they contain &ohgr;-,and &ohgr;-3 long chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergetic effect.

Methods for reducing the incidence of necrotizing enterocolitis

The invention is directed to an improved infant formula containing a lipid blend that softens the firmer stools associated with typical infant formula. A specific formula in accordance with the invention comprises carbohydrates, proteins, vitamins and minerals and a lipid mixture of high oleic safflower oil, soy oil and coconut oil at specific levels and ratios. The invention also discloses novel mixtures of fatty acids that provides infant stool patterns more closley resembling the breast-fed infant.

Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), as arachidonic acid (AA) and docosahexaenoic acid (DHA) that are essentially free of cholesterol, are described. More particularly, the invention relates to methods for reducing the incidence of necrotizing enterocolitis by administering compositions which provide .omega.-6 and .omega.-3 long chain PUFAs, phospholipids and/or choline. Compositions from egg yolk lipids are presently preferred as they contain .omega.-6 and .omega.-3 long chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergistic effect.

An improved enteral formula containing ribo-nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adducts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula. More specifically, an infant formula containing at least 10 milligrams of nucleotide equivalents per 100 Kcal of formula where the nucleotide equivalents consist of RNA; mono-, di-, and triphosphate esters of adenosine, cytidine, guanosine, and uridine, and the d-ribose adducts thereof; and wherein the weight ratio of said cytidine nucleotide equivalents to said uridine nucleotide equivalents is 1.5:1 to 2.6:1; of said cytidine nucleotide equivalent to said adenosine nucleotide equivalents is 2:1 to 3.9:1; and of said cytidine nucleotide equivalents to said guanosine nucleotide equivalents is 1.75:1 to 2.8:1, is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) ribo-nucleotide equivalents at specific levels and ratios. This invention also provides a dietary formula that enhances the immune system and alleviates diarrhea.

Nutritional formula with ribo-nucleotides

An improved enteral nutritional formula containing ribo-nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adjuncts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) ribo-nucleotide equivalents at specific levels and ratios. The invention also discloses novel methods of production and analytical techniques. An infant formula containing cytidine nucleotide equivalents in the range of 29 to 39 mg/liter of formula, uridine nucleotide equivalents in the range of 15 to 20 mg/liter of formula, adenosine nucleotide equivalents in the range of 10 to 15 mg/liter of formula and guanosine nucleotide equivalents in the range of 14 to 20 mg/liter of formula provides a dietary formula that enhances the immune system and alleviates diarrhea.

Infant nutritional formula with ribo-nucleotides

A hypercaloric formula providing nutritional support for human infants having chronic lung disease, said formula having a caloric density of at least 800 kcalories per liter of formula and wherein not less than 56% of the total calories in said formula is derived from fat; not more than 15% of total calories is derived from a high quality protein source; and from about 20-27% of total calories is from a carbohydrate source; said formula having a calcium to phosphorous ratio in the range of 1.4 to 2.2, and having an m-inositol concentration of at least 50 milligrams per liter of formula.

Nutritional product for human infants having chronic lung disease

A novel liquid nutritional for use as an infant formula for use in the treatment of infantile colic is disclosed. The formula comprises protein, fat, carbohydrates and dietary fiber of a concentration of between 3.1 and 14.1 grams of fiber per liter of formula. Specific preferred protein, fat, carbohydrate and fiber sources are disclosed. Also disclosed is a method of treating infants with colic by feeding an infant the formula made in accordance with the invention. Also disclosed is a method for manufacturing the infant formula of the invention.

Growing community of inventors

Powell, OH, United States of America

John D Benson